136 related articles for article (PubMed ID: 35818641)
1. Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
McQuilten Z; Wellard C; Moore E; Augustson B; Bergin K; Blacklock H; Harrison S; Ho PJ; King T; Quach H; Mollee P; Rosengarten B; Walker P; Wood E; Spencer A;
Br J Haematol; 2022 Sep; 198(5):830-837. PubMed ID: 35818641
[TBL] [Abstract][Full Text] [Related]
2. Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry.
Lim SL; Wellard C; Moore E; Harrison SJ; Hang Q; Ho J; Rajagopal R; Spencer A
Intern Med J; 2024 May; 54(5):773-778. PubMed ID: 38149340
[TBL] [Abstract][Full Text] [Related]
3. The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).
Bergin K; Wellard C; Moore E; McQuilten Z; Blacklock H; Harrison SJ; Ho PJ; King T; Quach H; Mollee P; Walker P; Wood E; Spencer A;
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e510-e520. PubMed ID: 33785297
[TBL] [Abstract][Full Text] [Related]
4. Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.
Bergin K; Moore E; McQuilten Z; Wood E; Augustson B; Blacklock H; Ho J; Horvath N; King T; McNeil J; Mollee P; Quach H; Reid CM; Rosengarten B; Walker P; Spencer A
BMC Med Res Methodol; 2016 Nov; 16(1):151. PubMed ID: 27829380
[TBL] [Abstract][Full Text] [Related]
5. Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
Moore EM; Blacklock H; Wellard C; Spearing R; Merriman L; Poplar S; George A; Baker B; Chan H; McQuilten ZK; Wood EM; Spencer A;
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e762-e769. PubMed ID: 35501256
[TBL] [Abstract][Full Text] [Related]
6. A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma.
Grant SJ; Wildes TM; Rosko AE; Silberstein J; Giri S
Cancer; 2023 Jul; 129(13):2023-2034. PubMed ID: 36989073
[TBL] [Abstract][Full Text] [Related]
7. Recognition of early mortality in multiple myeloma by a prediction matrix.
Terebelo H; Srinivasan S; Narang M; Abonour R; Gasparetto C; Toomey K; Hardin JW; Larkins G; Kitali A; Rifkin RM; Shah JJ
Am J Hematol; 2017 Sep; 92(9):915-923. PubMed ID: 28543165
[TBL] [Abstract][Full Text] [Related]
8. Changing survival of people with myeloma and end stage kidney disease: A cohort study using Australian and New Zealand dialysis and transplant registry 1963-2013.
Webster AC; Irish AB; Kelly PJ
Nephrology (Carlton); 2018 Mar; 23(3):217-225. PubMed ID: 28004444
[TBL] [Abstract][Full Text] [Related]
9. The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR).
Aoki N; Chen PY; Chen W; Chng WJ; Gan GG; Goh YT; Hou J; Huang J; Kim K; Lee JJ; Lu J; McQuilten ZK; Min CK; Moore E; Oliver L; Waters NA; Wellard C; Wood EM; Yeh SP; Spencer A;
BMC Med Res Methodol; 2024 May; 24(1):102. PubMed ID: 38698331
[TBL] [Abstract][Full Text] [Related]
10. Development of a prognostic model for overall survival in multiple myeloma using the Connect
Terebelo HR; Abonour R; Gasparetto CJ; Toomey K; Durie BGM; Hardin JW; Jagannath S; Wagner L; Narang M; Flick ED; Srinivasan S; Yue L; Kitali A; Agarwal A; Rifkin RM;
Br J Haematol; 2019 Dec; 187(5):602-614. PubMed ID: 31382320
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and risk factors for the development of infectious complications in newly diagnosed multiple myeloma: a multicenter prospective cohort study in Uruguay.
Riva E; Garrido D; Villano F; Bove V
Hematol Transfus Cell Ther; 2023 Oct; ():. PubMed ID: 38307822
[TBL] [Abstract][Full Text] [Related]
12. Lack of Renal Recovery Predicts Poor Survival in Patients of Multiple Myeloma With Renal Impairment.
Sharma R; Jain A; Jandial A; Lad D; Khadwal A; Prakash G; Nada R; Aggarwal R; Ramachandran R; Varma N; Malhotra P
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):626-634. PubMed ID: 35610119
[TBL] [Abstract][Full Text] [Related]
13. Impact of Socioeconomic Characteristics and Comorbidities on Therapy Initiation and Outcomes of Newly Diagnosed Multiple Myeloma: Real-World Data From a Resource-Constrained Setting.
Vargas-Serafin C; Acosta-Medina AA; Ordonez-Gonzalez I; Martínez-Baños D; Bourlon C
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):182-187. PubMed ID: 33414064
[TBL] [Abstract][Full Text] [Related]
14. Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States.
Medhekar R; Ran T; Fu AZ; Patel S; Kaila S
BMC Cancer; 2022 Aug; 22(1):901. PubMed ID: 35982416
[TBL] [Abstract][Full Text] [Related]
15. Patient survival on haemodiafiltration and haemodialysis: a cohort study using the Australia and New Zealand Dialysis and Transplant Registry.
See EJ; Hedley J; Agar JWM; Hawley CM; Johnson DW; Kelly PJ; Lee VW; Mac K; Polkinghorne KR; Rabindranath KS; Sud K; Webster AC
Nephrol Dial Transplant; 2019 Feb; 34(2):326-338. PubMed ID: 30124954
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.
Quach H; Horvath N; Cannell P; Mikhael JR; Butcher BE; Prince HM
Intern Med J; 2009 May; 39(5):290-5. PubMed ID: 19371392
[TBL] [Abstract][Full Text] [Related]
17. Effect of centre- and patient-related factors on uptake of haemodiafiltration in Australia and New Zealand: A cohort study using ANZDATA.
Mac K; Hedley J; Kelly PJ; Lee VW; Agar JWM; Hawley CM; Johnson DW; See EJ; Polkinghorne KR; Rabindranath KS; Sud K; Webster AC
Nephrology (Carlton); 2020 Jan; 25(1):63-72. PubMed ID: 30838737
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and Mortality of Staphylococcus aureus Bacteremia in Australian and New Zealand Children.
McMullan BJ; Bowen A; Blyth CC; Van Hal S; Korman TM; Buttery J; Voss L; Roberts S; Cooper C; Tong SY; Turnidge J
JAMA Pediatr; 2016 Oct; 170(10):979-986. PubMed ID: 27533601
[TBL] [Abstract][Full Text] [Related]
19. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
Ho PJ; Moore EM; McQuilten ZK; Wellard C; Bergin K; Augustson B; Blacklock H; Harrison SJ; Horvath N; King T; Mollee P; Quach H; Reid C; Rosengarten B; Walker P; Wood EM; Spencer A
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e415-e424. PubMed ID: 31208889
[TBL] [Abstract][Full Text] [Related]
20. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
